P&T
Our
Other
Journal
MediMedia Managed Markets
Managed Care

 

COPD inhalers – hold your breath

MANAGED CARE February 2014. © MediMedia USA
The Formulary Files

COPD inhalers – hold your breath

Krishna R. Patel, PharmD, RPh

With the approval of Breo Ellipta in May 2013 and Anoro Ellipta in December 2013, formulary decision makers are faced with more treatment options for chronic obstructive pulmonary disease (COPD) than ever before. There are now three inhalers that are combination products of a long-acting beta agonist and a glucocorticoid that can potentially help patients with moderate to severe COPD. Research comparing these available therapeutic options is limited, making differentiation difficult. Despite that, let’s take a look at several notable differences among these drugs.

Administration once daily Administration twice daily Black box warning Approved for COPD Approved for asthma Recommended in GOLD guidelines for moderate–severe COPD
Advair
Breo Ellipta
Symbicort
Source: GOLD (Global Initiative for Chronic Obstructive Lung Disease)